Dr. Abbas Bitar, M.D
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
1500 E Medical Center Drive, 3rd Floor Cardiovascular Center
Ann Arbor, MI 48109
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 289
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
MI license 4301109146 -
Cardiovascular Disease Physician
MI license 4301109146 -
Internal Medicine Physician
MI license 4301109146 -
Student in an Organized Health Care Education/Training Program
IN license 11015337A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
- Beaumont Hospital, Troy Troy, MI
- Beaumont Hospital - Dearborn Dearborn, MI
- Chelsea Hospital Chelsea, MI
- Promedica Charles and Virginia Hickman Hospital Adrian, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 289
- Services billed
- 817
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 244 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 205 | 174 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 145 | 133 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 52 | 15 |
| Telephone medical discussion with physician, 21-30 minutes | 48 | 45 |
| New patient office or other outpatient visit, 60-74 minutes | 39 | 39 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
| Hospital discharge day management, more than 30 minutes | 23 | 22 |
| Insertion of tube in right heart chambers for measurement | 22 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $226,543 in research payments for these studies, mostly to the institutions running them.
- Innovate
Briohealth Solutions, Inc. - Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Procyrion, Inc. · Recruiting · NCT05677100 - Clinical ENGAGEmENt in An LDL Cholesterol Treatment GuidEline IMplementation PrOgram With PatiEnts at High Risk for a Future Atherosclerotic Cardiovascular Disease (ASCVD) Event (E3: ENGAGE ENACT EMPOWER)
Amgen Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.